Quest Laboratories Ltd
Incorporated in 1998, Quest Laboratories Ltd is a pharmaceutical manufacturer specializing in diverse therapeutic segments[1]
- Market Cap ₹ 164 Cr.
- Current Price ₹ 99.9
- High / Low ₹ 160 / 75.2
- Stock P/E 12.1
- Book Value ₹ 49.9
- Dividend Yield 0.00 %
- ROCE 26.9 %
- ROE 24.6 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.0%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 109 days to 245 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 30 | 59 | 62 | 83 | 104 | |
| 29 | 53 | 54 | 67 | 88 | |
| Operating Profit | 1 | 6 | 8 | 16 | 16 |
| OPM % | 5% | 11% | 13% | 19% | 15% |
| 0 | 0 | 0 | 0 | 4 | |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 1 | 6 | 7 | 14 | 19 |
| Tax % | 18% | 29% | 28% | 30% | 27% |
| 1 | 4 | 5 | 10 | 14 | |
| EPS in Rs | 8.45 | 8.28 | |||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 49% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 32% |
| Last Year: | 25% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 12 | 16 |
| Reserves | 5 | 9 | 14 | 17 | 65 |
| 3 | 3 | 4 | 5 | 30 | |
| 9 | 22 | 28 | 26 | 10 | |
| Total Liabilities | 18 | 35 | 47 | 59 | 122 |
| 6 | 7 | 10 | 10 | 12 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 52 |
| 12 | 27 | 37 | 49 | 58 | |
| Total Assets | 18 | 35 | 47 | 59 | 122 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 1 | 3 | 4 | 3 | -23 | |
| -1 | -2 | -4 | -5 | -44 | |
| 0 | -0 | 0 | 2 | 67 | |
| Net Cash Flow | -0 | 1 | 0 | 0 | -0 |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 110 | 135 | 118 | 104 | 105 |
| Inventory Days | 12 | 9 | 97 | 113 | 99 |
| Days Payable | 119 | 140 | 215 | 137 | 26 |
| Cash Conversion Cycle | 3 | 4 | 1 | 79 | 178 |
| Working Capital Days | 9 | 14 | 27 | 57 | 245 |
| ROCE % | 55% | 47% | 58% | 27% |
Documents
Announcements
-
Updates
5 August 2025 - Quest Labs reports July sales Rs 4.52 Cr, 42% YoY growth; Apr-Jul sales up 81.64%.
-
Analysts/Institutional Investor Meet/Con. Call Updates
30 July 2025 - Analyst meeting with V Square Wealth on 2 Aug 2025; no unpublished info to be shared.
-
Investor Presentation
25 July 2025 - Quest Labs July 2025 investor presentation: strong growth, new capsule line, USFDA injectable facility, export expansion.
-
Outcome of Board Meeting
24 July 2025 - Q1 FY2026 unaudited results: Profit INR 410.43 lakhs; land acquired for INR 321.20 lakhs expansion.
-
Outcome of Board Meeting
24 July 2025 - Q1 FY26 unaudited results: Profit ₹410.43L, EPS ₹2.50; land bought for ₹321.20L for expansion.
Business Overview:[1][2]
a) QLL specializes in manufacturing a wide range of pharmaceutical formulations, including antibiotics, antimalarials, anti-inflammatories, respiratory medications,
diabetes treatments, and more.
b) Company also produces a wide range of ethical, generic, and over-the-counter (OTC) drugs in various forms, including tablets, liquids, oral powders, ORS, ointments, and external liquids.
c) Quest offers facilities for institutional supplies, domestic ethical products, PCD, Contract manufacturing, and export, with
a focus on a wide range of specialized formulations and molecules
d) The company has 800+ Licensed Formulations, 272+ Active Products, 25cr.+Order Book from Myanmar